Capvex 500

Capvex 500



Vexxa Lifesciences


VE Pharma
Concise Prescribing Info
Treatment of metastatic breast cancer resistant to both paclitaxel & anthracycline-containing chemotherapy regimen. In combination w/ docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relapsed during or following anthracycline-containing chemotherapy. Adjuvant therapy following the complete resection of primary tumor in patients w/ stage III colon cancer when monotherapy w/ fluoropyrimidine is preferred.
Dosage/Direction for Use
Individualized dosage. Monotherapy 1,250 mg/m2 bid for 2 wk followed by 1-wk rest period in 3-wk cycles. Adjuvant treatment Total of 6 mth (8 cycles). In combination w/ docetaxel 1,250 mg/m2 bid for 2 wk followed by a 7-day rest period, in combination w/ docetaxel 75 mg/m2 as 1-hr IV infusion every 3 wk.
Should be taken with food: Take w/in 30 min after meals w/ water.
Hypersensitivity to capecitabine & 5-fluorouracil.
Special Precautions
Concomitant use w/ coumarin-derivative anticoagulants. May induce (severe) diarrhea & necrotizing enterocolitis occur. Cardiotoxicity associated w/ fluorinated-pyrimidine therapy including MI, angina, dysrhythmias, cardiogenic shock, sudden death & ECG changes. Hyperbilirubinemia, neutropenia, thrombocytopenia, decreased Hb. Hepatic & renal impairment. Impairment of fertility. Pregnancy & lactation. Childn <18 yr. Elderly ≥80 yr.
Adverse Reactions
Diarrhea, nausea, vomiting, stomatitis, abdominal pain, constipation, dyspepsia; hand-&-foot syndrome, dermatitis, nail disorder; fatigue, pyrexia, pain in limb; paresthesia, headache, dizziness, insomnia; anorexia, dehydration; eye irritation; myalgia; edema, blood, neutropenia, thrombocytopenia, anemia, lymphopenia; hyperbilirubinemia.
Drug Interactions
Increased plasma conc w/ antacids (eg Al- & Mg hydroxide-containing antacids). Alterations in coagulation parameters &/or bleeding w/ coumarin anticoagulants eg warfarin & phenprocoumon. Concomitant use w/ phenytoin. Increased conc of 5-fluorouracil & toxicity may be enhanced by leucovorin.
ATC Classification
L01BC06 - capecitabine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer.
Capvex 500 FC tab 500 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in